215 related articles for article (PubMed ID: 32697965)
1. Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial.
Ruppert R; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Junginger T; Hermanek P; Merkel S;
J Am Coll Surg; 2020 Oct; 231(4):413-425.e2. PubMed ID: 32697965
[TBL] [Abstract][Full Text] [Related]
2. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
[TBL] [Abstract][Full Text] [Related]
3. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
4. MRI-Based Use of Neoadjuvant Chemoradiotherapy in Rectal Carcinoma: Surgical Quality and Histopathological Outcome of the OCUM Trial.
Kreis ME; Ruppert R; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Winde G; Thomasmeyer R; Stelzner S; Bambauer C; Scheunemann S; Faedrich A; Junginger T; Hermanek P; Merkel S;
Ann Surg Oncol; 2020 Feb; 27(2):417-427. PubMed ID: 31414295
[TBL] [Abstract][Full Text] [Related]
5. MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary?
Zeng Z; Li Z; Luo S; Huang L; Liang Z; Zheng X; Li W; Xiong L; Liu H; Kang L
J Gastroenterol Hepatol; 2024 May; 39(5):858-867. PubMed ID: 38225773
[TBL] [Abstract][Full Text] [Related]
6. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
Lin Y; Lin H; Xu Z; Zhou S; Chi P
J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
[No Abstract] [Full Text] [Related]
7. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
8. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
9. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
[TBL] [Abstract][Full Text] [Related]
10. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
11. Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study.
Ruppert R; Junginger T; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Lauscher J; Winde G; Thomasmeyer R; Stelzner S; Bambauer C; Scheunemann S; Faedrich A; Wollschlaeger D; Merkel S
J Clin Oncol; 2023 Aug; 41(24):4025-4034. PubMed ID: 37335957
[TBL] [Abstract][Full Text] [Related]
12. Do We Have to Treat All T3 Rectal Cancer the Same Way?
Valadão M; Dias JA; Araújo R; Cesar D
Clin Colorectal Cancer; 2020 Dec; 19(4):231-235. PubMed ID: 32839078
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
[TBL] [Abstract][Full Text] [Related]
16. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.
Ogura A; Konishi T; Beets GL; Cunningham C; Garcia-Aguilar J; Iversen H; Toda S; Lee IK; Lee HX; Uehara K; Lee P; Putter H; van de Velde CJH; Rutten HJT; Tuynman JB; Kusters M;
JAMA Surg; 2019 Sep; 154(9):e192172. PubMed ID: 31268504
[TBL] [Abstract][Full Text] [Related]
17. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
18. Limited Role for Routine Restaging After Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Caturegli I; Molin MD; Laird C; Molitoris JK; Bafford AC
J Surg Res; 2020 Dec; 256():317-327. PubMed ID: 32712447
[TBL] [Abstract][Full Text] [Related]
19. Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma.
Swords DS; Skarda DE; Sause WT; Gawlick U; Cannon GM; Lewis MA; Scaife CL; Gygi JA; Tae Kim H
J Gastrointest Surg; 2019 Apr; 23(4):659-669. PubMed ID: 30706375
[TBL] [Abstract][Full Text] [Related]
20. Defining and predicting early recurrence in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Zheng Z; Wang X; Huang Y; Lu X; Huang Z; Chi P
Eur J Surg Oncol; 2020 Nov; 46(11):2057-2063. PubMed ID: 32782202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
